查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1819995

急性骨髓性白血病治疗市场报告（依治疗类型、药物类型、给药途径及地区划分）2025-2033

Acute Myeloid Leukemia Therapeutics Market Report by Treatment Type, Drug Type, Route of Administration, and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 137 Pages | 商品交期: 2-3个工作天内

价格

2024 年全球急性骨髓性白血病治疗市场规模达 13.436 亿美元。展望未来， IMARC Group预计到 2033 年市场规模将达到 34.614 亿美元，2025-2033 年期间的成长率 (CAGR) 为 10.53%。

急性骨髓性白血病 (AML) 是一种导致异常细胞快速生长的克隆性恶性肿瘤。它主要影响骨髓和白血球 (WBC)，其特征包括皮肤变色、呼吸困难、疲劳、体温升高、体重减轻、牙龈出血和流鼻血。常用的 AML 疗法包括化疗、免疫疗法、标靶疗法、荷尔蒙疗法和外科手术。这些疗法通常与干细胞移植相结合，以提高疗效、减少併发症并增强人体免疫系统。

全球白血病盛行率的上升是推动市场成长的关键因素之一。此外，老年人口的不断增长也推动了市场的成长，老年人更容易患上此类疾病。急性髓性白血病 (AML) 主要由体内基因突变引起，该突变会影响血球生成水平。同时，联合疗法和标靶疗法的广泛应用，以及人们对癌症治疗替代方案的认识不断提高，也有利于市场的成长。此外，改良免疫毒素、烷化剂、单株抗体和多重抗药性调节剂的出现是另一个重要的成长诱因。这些疗法能够提供更持久的疗效、更高的疗效、早期准确识别白血病细胞，并降低癌症復发的可能性。其他因素，包括肿瘤学领域的广泛研发活动，以及现有医疗基础设施的显着改善，预计将进一步推动市场成长。

本报告回答的关键问题：

  • 全球急性髓性白血病治疗市场迄今表现如何？未来几年将如何表现？
  • COVID-19 对全球急性骨髓性白血病治疗市场有何影响？
  • 主要的区域市场有哪些？
  • 根据治疗类型，市场是如何分類的？
  • 根据药物类型，市场是如何分類的？
  • 根据行政路径，市场如何划分？
  • 该产业的价值链分为哪些阶段？
  • 该行业的主要驱动因素和挑战是什么？
  • 全球急性骨髓性白血病治疗市场的结构是怎么样的？主要参与者是谁？
  • 产业竞争程度如何？

目录

第一章：前言

第二章：范围与方法

  • 研究目标
  • 利害关係人
  • 资料来源
    • 主要来源
    • 二手资料
  • 市场评估
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第三章：执行摘要

第四章：简介

第五章：全球急性骨髓性白血病治疗市场

  • 市场概况
  • 市场表现
  • COVID-19的影响
  • 市场预测

第六章：市场区隔：依治疗类型

  • 阿糖胞苷
  • 蒽环类药物
  • 烷化剂
  • 抗代谢物
  • 酪胺酸激酶抑制剂
  • 其他的

第七章：市场区隔：依药物类型

  • 小分子药物
  • 生物製药

第八章：市场区隔：依行政途径

  • 口服
  • 注射剂

第九章：市场细分：依地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲

第 10 章：SWOT 分析

第 11 章：价值链分析

第 12 章：波特五力分析

第十三章：价格分析

第 14 章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Abbvie Inc.
    • Amgen Inc.
    • Bristol-Myers Squibb Company
    • Celgene
    • Roche Holding AG
    • Gilead Sciences Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi SA
    • Takeda Pharmaceutical Company Limited
Product Code: SR112025A3129

The global acute myeloid leukemia therapeutics market size reached USD 1,343.6 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 3,461.4 Million by 2033, exhibiting a growth rate (CAGR) of 10.53% during 2025-2033.

Acute myeloid leukemia (AML) refers to a clonal malignancy leading to the rapid growth of abnormal cells. It primarily impacts the bone marrow and white blood cells (WBCs) and is characterized by the discoloration of skin, breathlessness, fatigue, high body temperatures, weight loss, bleeding gums and nosebleeds. Some of the commonly used AML therapies include chemo-, immuno-, targeted- and hormonal therapies and surgical procedures. These therapeutics are usually combined with stem cell transplants to increase the efficacy, minimize complications and strengthen the immune system of the body.

The increasing prevalence of leukemia across the globe represents one of the key factors driving the growth of the market. Furthermore, the rising geriatric population, which is more susceptible to such disorders, is also driving the market growth. AML is primarily caused by genetic mutations in the body that impacts the levels of blood cell production. In line with this, the widespread adoption of combination and targeted therapies and increasing awareness regarding the available alternatives for cancer treatment are also favoring the market growth. Additionally, the advent of improved immunotoxins, alkylating agents, monoclonal antibodies and multidrug-resistant modulators is another major growth-inducing factor. These therapeutics offer prolonged results, higher efficacy, early and accurate identification of leukemia cells and reduced chances of cancer relapse. Other factors, including extensive research and development (R&D) activities in the field of oncology, along with significant improvements in the existing healthcare infrastructure, are anticipated to drive the market further.

Key Market Segmentation:

Breakup by Treatment Type:

  • Cytarabine
  • Anthracycline Drugs
  • Alkylating Agents
  • Anti-Metabolites
  • Tyrosine Kinase Inhibitors
  • Others

Breakup by Drug Type:

  • Small Molecule Drugs
  • Biopharmaceuticals

Breakup by Route of Administration:

  • Oral
  • Injectables

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbvie Inc., Amgen Inc., Bristol-Myers Squibb Company, Celgene, Roche Holding AG, Gilead Sciences Inc., Novartis AG, Pfizer Inc., Sanofi S.A. and Takeda Pharmaceutical Company Limited.

Key Questions Answered in This Report:

  • How has the global acute myeloid leukemia therapeutics market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global acute myeloid leukemia therapeutics market?
  • What are the key regional markets?
  • What is the breakup of the market based on the treatment type?
  • What is the breakup of the market based on the drug type?
  • What is the breakup of the market based on the route of administration?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global acute myeloid leukemia therapeutics market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Acute Myeloid Leukemia Therapeutics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Treatment Type

  • 6.1 Cytarabine
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Anthracycline Drugs
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Alkylating Agents
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Anti-Metabolites
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Tyrosine Kinase Inhibitors
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Others
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast

7 Market Breakup by Drug Type

  • 7.1 Small Molecule Drugs
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Biopharmaceuticals
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Route of Administration

  • 8.1 Oral
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Injectables
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Abbvie Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Amgen Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Bristol-Myers Squibb Company
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Celgene
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 SWOT Analysis
    • 14.3.5 Roche Holding AG
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
    • 14.3.6 Gilead Sciences Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Novartis AG
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
    • 14.3.8 Pfizer Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Sanofi S.A.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
    • 14.3.10 Takeda Pharmaceutical Company Limited
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Acute Myeloid Leukemia Therapeutics Market: Major Drivers and Challenges
  • Figure 2: Global: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million USD), 2019-2024
  • Figure 3: Global: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 4: Global: Acute Myeloid Leukemia Therapeutics Market: Breakup by Treatment Type (in %), 2024
  • Figure 5: Global: Acute Myeloid Leukemia Therapeutics Market: Breakup by Drug Type (in %), 2024
  • Figure 6: Global: Acute Myeloid Leukemia Therapeutics Market: Breakup by Route of Administration (in %), 2024
  • Figure 7: Global: Acute Myeloid Leukemia Therapeutics Market: Breakup by Region (in %), 2024
  • Figure 8: Global: Acute Myeloid Leukemia Therapeutics (Cytarabine) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 9: Global: Acute Myeloid Leukemia Therapeutics (Cytarabine) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 10: Global: Acute Myeloid Leukemia Therapeutics (Anthracycline Drugs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Acute Myeloid Leukemia Therapeutics (Anthracycline Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: Acute Myeloid Leukemia Therapeutics (Alkylating Agents) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Acute Myeloid Leukemia Therapeutics (Alkylating Agents) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: Acute Myeloid Leukemia Therapeutics (Anti-Metabolites) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Acute Myeloid Leukemia Therapeutics (Anti-Metabolites) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Acute Myeloid Leukemia Therapeutics (Tyrosine Kinase Inhibitors) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Acute Myeloid Leukemia Therapeutics (Tyrosine Kinase Inhibitors) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Acute Myeloid Leukemia Therapeutics (Others) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Acute Myeloid Leukemia Therapeutics (Others) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Acute Myeloid Leukemia Therapeutics (Small Molecule Drugs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Acute Myeloid Leukemia Therapeutics (Small Molecule Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: Global: Acute Myeloid Leukemia Therapeutics (Biopharmaceuticals) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: Global: Acute Myeloid Leukemia Therapeutics (Biopharmaceuticals) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: Global: Acute Myeloid Leukemia Therapeutics (Oral) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: Global: Acute Myeloid Leukemia Therapeutics (Oral) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: Global: Acute Myeloid Leukemia Therapeutics (Injectables) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: Global: Acute Myeloid Leukemia Therapeutics (Injectables) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: North America: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: North America: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: United States: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: United States: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: Canada: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: Canada: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: Asia-Pacific: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: Asia-Pacific: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: China: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: China: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: Japan: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: Japan: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: India: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: India: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: South Korea: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: South Korea: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: Australia: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: Australia: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: Indonesia: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: Indonesia: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: Others: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: Others: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: Europe: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: Europe: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: Germany: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: Germany: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: France: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: France: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: United Kingdom: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: United Kingdom: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: Italy: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: Italy: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: Spain: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: Spain: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: Russia: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: Russia: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: Others: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: Others: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: Latin America: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: Latin America: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: Brazil: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 69: Brazil: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 70: Mexico: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 71: Mexico: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 72: Others: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 73: Others: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 74: Middle East and Africa: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 75: Middle East and Africa: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 76: Middle East and Africa: Acute Myeloid Leukemia Therapeutics Market: Breakup by Country (in %), 2024
  • Figure 77: Global: Acute Myeloid Leukemia Therapeutics Industry: SWOT Analysis
  • Figure 78: Global: Acute Myeloid Leukemia Therapeutics Industry: Value Chain Analysis
  • Figure 79: Global: Acute Myeloid Leukemia Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Acute Myeloid Leukemia Therapeutics Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Acute Myeloid Leukemia Therapeutics Market Forecast: Breakup by Treatment Type (in Million USD), 2025-2033
  • Table 3: Global: Acute Myeloid Leukemia Therapeutics Market Forecast: Breakup by Drug Type (in Million USD), 2025-2033
  • Table 4: Global: Acute Myeloid Leukemia Therapeutics Market Forecast: Breakup by Route of Administration (in Million USD), 2025-2033
  • Table 5: Global: Acute Myeloid Leukemia Therapeutics Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 6: Global: Acute Myeloid Leukemia Therapeutics Market: Competitive Structure
  • Table 7: Global: Acute Myeloid Leukemia Therapeutics Market: Key Players